US2005203121A1PendingUtilityA1

Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases

58
Priority: Dec 3, 1998Filed: Apr 19, 2005Published: Sep 15, 2005
Est. expiryDec 3, 2018(expired)· nominal 20-yr term from priority
Inventors:Iok-Hou Pang
A61K 31/52
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions and methods for the treatment of retina and optic nerve head neuropathy are disclosed. The compositions and methods are particularly directed to the use of neurotrophic factor stimulators, such as AIT-082 (neotrofin), in the treatment of glaucomatous neuropathy.

Claims

exact text as granted — not AI-modified
1 . A composition for the treatment of retina or optic nerve head neuropathy comprising an effective amount of one or more neurotrophic factor stimulator(s) and a pharmaceutically acceptable vehicle.  
     
     
         2 . A composition according to  claim 1 , wherein the neurotrophic factor stimulator is selected from the group consisting of AIT-082 (neotrofin), idebenone, ONO-2506, CB-1093, NS521 ((1-(1-butyl)-4-(2-oxo-1-benzimidazolone) piperidine, SS-701, KT-711 and clenbuterol.  
     
     
         3 . A composition according to  claim 2 , wherein the neurotrophic factor stimulator is AIT-082 (neotrofin).  
     
     
         4 . A composition according to  claim 1 , wherein the composition is an oral formulation.  
     
     
         5 . A composition according to  claim 1 , wherein the composition is a topical ophthalmic, or intraocular formulation.  
     
     
         6 . A composition according to  claim 3 , wherein the composition is an oral formulation.  
     
     
         7 . A composition according to  claim 3 , wherein the composition is a topical ophthalmic, or intraocular formulation.  
     
     
         8 . A method for the treatment of retina or optic nerve head neuropathy which comprises administering to a mammal a composition comprising an effective amount of one or more neurotrophic factor stimulator(s) and a pharmaceutically acceptable vehicle.  
     
     
         9 . A method according to  claim 8 , wherein the neurotrophic factor stimulator is selected from the group consisting of: AIT-082 (neotrofin), idebenone, ONO-2506, CB-1093, NS521 ((1-(1-butyl)-4-(2-oxo-1-benzimidazolone) piperidine, SS-701, KT-711 and clenbuterol.  
     
     
         10 . A method according to  claim 9 , wherein the neurotrophic factor stimulator is AIT-082 (neotrofin).  
     
     
         11 . A method according to  claim 8 , wherein the composition is an oral formulation.  
     
     
         12 . A method according to  claim 8 , wherein the composition is a topical ophthalmic, or intraocular formulation.  
     
     
         13 . A method according to  claim 10 , wherein the composition is an oral formulation.  
     
     
         14 . A method according to  claim 10 , wherein the composition is a topical ophthalmic, or intraocular formulation.

Join the waitlist — get patent alerts

Track US2005203121A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.